Important drug interactions in patients with rheumatic disorders: Interactions of glucocorticoids, immunosuppressants and antimalarial drugs

Drugs of Today

Volumn 48, Issue 8, 2012, Pages 545-553

  Hromadkova, Lucie ^a   Soukup, T ^b   Vlcek, J ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antimalarial drugs; Antirheumatic drugs; Drug interactions; Glucocorticosteroids; Immunosuppressants

Indexed keywords

ACTIVATED CARBON; ALLOPURINOL; ALUMINUM; AMIODARONE; ANTIMALARIAL AGENT; AZATHIOPRINE; BOSENTAN; COLESTYRAMINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IRON; LEFLUNOMIDE; MAGNESIUM; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISONE; PROTON PUMP INHIBITOR; PYRROLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SALAZOSULFAPYRIDINE; UNINDEXED DRUG; WARFARIN;

CLINICAL PRACTICE; DATA BASE; HUMAN; REVIEW; RHEUMATIC DISEASE;

ANTIMALARIALS; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 84866458626     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.8.1841300     Document Type: Review

References (44)

1. van Roon, E.N., van den Bemt, P.M.L.A., Jansen, T.L.Th.A., Houtman, N.M., van de Laar, M.A.F.J., Brouwers, J.R.B.J. Anevidence-based assessment of the clinical significance ofdrug-drug interactions between disease- modifyingantirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 2009, 31(8): 1737-46.
2. Haagsma, D.J. Clinically important drug interactions withdisease- modifying antirheumatic drugs. Drugs Aging 1998, 13(4): 281-9.
3. DRUGDEX® System [intranet database]. Version 5.1. Thomson Reuters, Greenwood Village, Colorado.
4. Composite authors. InfoPharm Compendium of Drug interactions. Prague 2010.
5. Hazlewood, K.A., Fugate, S.E., Harrison, D.L. Effect of oralcorticosteroids on chronic warfarin therapy. Ann Pharmacother 2006, 40(12): 2101-6. (Pubitemid 44954426)
6. Kaufman, M. Treatment of multiple sclerosis with high-dosecorticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler 1997, 3(4): 248-9.
7. Costedoat-Chalumeau, N., Amoura, Z., Aymard, G. et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Int Med 2000, 132(8): 631-5. (Pubitemid 30217555)
8. Carson, J.L., Strom, B.L., Schinnar, R., Duff, A., Sim, E. Thelow risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 1991, 91(3): 223-8.
9. van der Linden, P.D., Sturkenboom, M.C.J.M., Herings, R.M.C., Leufkens, H.G.M., Stricker, B.H.Ch. Fluoroquinolones and risk of Achilles tendon disorders: case-controlstudy. Br Med J 2002, 324(7349): 1306-7. (Pubitemid 34606771)
10. Blanco I, Krähenbühl S, Schlienger RG. Corticosteroid- associated tendinopathies, an analysis of the published literatureand spontaneous pharmacovigilance data. Drug Safety 2005, 28(7): 633-43. (Pubitemid 41003049)
11. Lebrun-Vignes, B., Archer, V.C., Diquet, B., Levron, J.C., Chosidow, O., Puech, A.J., Warot, D. Effect of itraconazole onthe pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001, 51(5): 443-50. (Pubitemid 32852982)
12. Varis, T., Kivistö, K.T., Neuvonen, P.J. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oralprednisolone. Eur J Clin Pharmacol 2000, 56(1): 57-60. (Pubitemid 30317782)
13. Glynn, A.M., Slaughter, R.L., Brass, C., D'Ambrosio, R., Jusko, W.J. Effect of ketoconazole on methylprednisolonepharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986, 36(6): 654-9. (Pubitemid 16097304)
14. Ulrich, B., Frey, F.J., Speck, R.F., Frey, B.M. Pharmacokinetics/ pharmacodynamics of ketoconazole-prednisoloneinteraction. J Pharmacol Exp Ther 1992, 260(2): 487-90.
15. Zurcher, R.M., Frey, B.M., Frey, F.J. Impact of ketoconazoleon the metabolism of prednisolone. Clin Pharmacol Ther 1989, 45(4): 366-72.
16. Ludwig, E.A., Slaughter, R.L., Savliwala, M., Brass, C., Jusko, W.J. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination.Drug Intel Clin Phar 1989, 23(11): 858-61. (Pubitemid 19284804)
17. Yamashita, S.K., Ludwig, E.A., Middleton, E. Jr., Jusko, W.J. Lack of pharmacokinetic and pharmacodynamic interactionsbetween ketoconazole and prednisolone. Clin Pharmacol Ther 1991, 49: 558-70.
18. Tiao, G.M., Martin, J., Weber, F.L., Cohen, R.M., Hanto, D.W. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clin Transplant 1999, 13(1): 62-4. (Pubitemid 29110391)
19. White, E.S., Lynch, J.P. Pharmacological therapy forWegener's granulomatosis. Drugs 2006, 66(9): 1209-28.
20. Bannwarth, B., Péhourcq, F., Schaeverbeke, T., Dehais, J. Clinical pharmacokinetics of low-dose pulse methotrexate inrheumatoid arthritis. Clin Pharmacokinet 1996, 30(3): 194- 210.
21. Steuer, A., Gumpel, J.M. Methotrexate and trimethoprim: Afatal interaction. Br J Rheumatol 1998, 37(1): 105-6.
22. Product information. Methotrexate Hospira (methotrexate). Hospira UK Limited, Royal Leamington Spa, Great Britain, August 2007.
23. Breedveld, P., Zelcer, N., Pluim, D. et al. Mechanism of thepharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004, 64(16): 5804-11. (Pubitemid 39095580)
24. Suzuki, K., Doki, K., Homma, M., Tamaki, H., Hori, S., Ohtani, H., Sawada, Y., Kohda, Y. Co-administration of proton pumpinhibitors delays elimination of plasma methotrexate in highdose methotrexate therapy. Br J Clin Pharmacol 2008, 67(1): 44-9.
25. Tröger, U., Stötzel, B., Martens-Lobenhoffer, J., Gollnick, H., Meyer, F.P. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 2002, 324(7352): 1497. (Pubitemid 34666620)
26. Vakily, M., Amer, F., Kukulka, M.J., Andhivarothai, N. Coadministration of lansoprazole and naproxen does not affectthe pharmacokinetic profile of methotrexate in adult patientswith rheumatoid arthritis. J Clin Pharmacol 2005, 45(10): 1179-86. (Pubitemid 41361918)
27. Product information. Cordarone (amiodarone). Sanofiaventis Inc., Prague, Czech Republic, April 2009.
28. Reynolds, N.J., Jones, S.K., Crossley, J., Harman, R.R. Methotrexate induced skin necrosis: a drug interaction withamiodarone? Br Med J 1989, 299(6705): 980-1. (Pubitemid 19246366)
29. Fuksa, L., Brcakova, E., Cermanova, J. et al. Amiodaronemodulates pharmacokinetics of low-dose methotrexate inrats. Biopharm Drug Dispos 2008, 29(5): 289-99.
30. Product information. Neotigason (acitretin). Actavis Group PTC ehf. Hafnarfjordur, Island, June 2009.
31. Chonlahan, J., Halloran, M.A., Hammonds, A. Leflunomideand warfarin interaction: case report and review of the literature.Pharmacotherapy 2006, 26(6): 868-71. (Pubitemid 43807637)
32. Gearry, R.B., Day, A.S., Barclay, M.L., Leong, R.W.L., Sparrow, M.P. Azathioprine and allopurinol: A two-edgedinteraction. J Gastroenterol Hepatol 2010, 25(4): 653-5.
33. Product information. Azaprine (azathioprine). TEVA Czech Industries Inc., Opava-Komárov, Czech Republic, April 2004.
34. Havrda, D.E., Rathhun, S., Scheid, D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 2001, 21(3): 355-7. (Pubitemid 32208850)
35. Gossmann, J., Kachel, H.G., Schoeppe, W., Scheuermann, E.H. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993, 56(3): 585-9. (Pubitemid 23293020)
36. Lindholm, A. Factors influencing the pharmacokinetics ofcyclosporine in man. Ther Drug Monit 1991, 13: 465-77.
37. Asberg, A. Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 2003, 63(4): 367-78. (Pubitemid 36259524)
38. Jardine, A., Holdaas, H. Fluvastatin in combination withcyclosporin in renal transplant recipients: a review of clinicaland safety experience. J Clin Pharm Ther 1999, 24(6): 397- 408.
39. Loadman, P.M., Bibby, M.C. Pharmacokinetic drug interactions with anticancer drugs . Clin Pharmacokinet 1994, 26(6): 486-500. (Pubitemid 24166337)
40. Juhl, R.P., Summers, R.W., Guillory, J.K., Seymour, M.B., Cheng, F.H., Brown, D.D. Effect of sulfasalazine on digoxinbioavailability. Clin Pharmacol Ther 1976, 20(4): 387-94.
41. Osman, M.A., Patel, R.B., Schuna, A., Sundstrom, W.R., Welling, P.G. Reduction in oral penicillamine absorption byfood, antacid, and ferrous sulfate. Clin Pharmacol Ther 1983, 33(4): 465-70. (Pubitemid 13093766)
42. Leden, I. Digoxin-hydroxychloroquine interaction? Acta Med Scand 1982, 211(5): 411-2. (Pubitemid 12127834)
43. McElnay, J.C., Sidahmed, A.M., D'Arcy, P.F., McQuade, R.D. Chloroquine-digoxin interaction. Int J Pharm 1985, 26(3): 267-74. (Pubitemid 16228625)
44. Kirwan, J.R. and the Arthritis and Rheumatism Council Low-dose Glucocorticosteroid Study Group. The effects ofglucocorticosteroids on joint destruction in rheumatoidarthritis. N Engl J Med 1995, 333(3): 142-6.